Recent Advances in the Treatment and Management of Alzheimer’s Disease: A Precision Medicine Perspective

美金刚 加兰他明 痴呆 竞争对手 医学 淀粉样蛋白(真菌学) 疾病 神经炎症 多奈哌齐 神经科学 阿尔茨海默病 生物信息学 心理学 病理 生物
作者
Deepali Shukla,Anjali Suryavanshi,Sanjay Kumar Bharti,Vivek Asati,Debarshi Kar Mahapatra
出处
期刊:Current Topics in Medicinal Chemistry [Bentham Science]
卷期号:24
标识
DOI:10.2174/0115680266299847240328045737
摘要

Abstract: About 60% to 70% of people with dementia have Alzheimer's Disease (AD), a neuro-degenerative illness. One reason for this disorder is the misfolding of naturally occurring proteins in the human brain, specifically β-amyloid (Aβ) and tau. Certain diagnostic imaging techniques, such as amyloid PET imaging, tau PET imaging, Magnetic Resonance Imaging (MRI), Comput-erized Tomography (CT), and others, can detect biomarkers in blood, plasma, and cerebral spinal fluids, like an increased level of β-amyloid, plaques, and tangles. In order to create new pharma-cotherapeutics for Alzheimer's disease, researchers must have a thorough and detailed knowledge of amyloid beta misfolding and other related aspects. Dolopezil, rivastigmine, galantamine, and other acetylcholinesterase inhibitors are among the medications now used to treat Alzheimer's disease. Another medication that can temporarily alleviate dementia symptoms is memantine, which blocks the N-methyl-D-aspartate (NMDA) receptor. However, it is not able to halt or re-verse the progression of the disease. Medication now on the market can only halt its advance-ment, not reverse it. Interventions to alleviate behavioral and psychological symptoms, exhibit an-ti-neuroinflammation and anti-tau effects, induce neurotransmitter alteration and cognitive en-hancement, and provide other targets have recently been developed. For some Alzheimer's pa-tients, the FDA-approved monoclonal antibody, aducanumab, is an option; for others, phase 3 clinical studies are underway for drugs, like lecanemab and donanemab, which have demonstrat-ed potential in eliminating amyloid protein. However, additional study is required to identify and address these limitations in order to reduce the likelihood of side effects and maximize the thera-peutic efficacy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Vivi应助XF采纳,获得10
1秒前
Yina完成签到 ,获得积分10
1秒前
喜宝发布了新的文献求助10
1秒前
1秒前
今后应助优雅的纸鹤采纳,获得10
2秒前
跳跃毒娘发布了新的文献求助10
2秒前
2秒前
3秒前
4秒前
drew发布了新的文献求助30
5秒前
bbj完成签到,获得积分10
5秒前
泊頔发布了新的社区帖子
5秒前
难过奎完成签到,获得积分10
5秒前
5秒前
研友_nEW4G8完成签到 ,获得积分10
5秒前
6秒前
7秒前
7秒前
Mao耶发布了新的文献求助10
7秒前
bbj发布了新的文献求助10
8秒前
9秒前
9秒前
傅傅发布了新的文献求助10
10秒前
jjj发布了新的文献求助30
10秒前
10秒前
11秒前
12秒前
tzq完成签到,获得积分10
12秒前
13秒前
13秒前
吃不饱星球球长应助loading采纳,获得10
13秒前
超帅的元柏完成签到,获得积分10
14秒前
14秒前
完美世界应助坚定的平松采纳,获得10
14秒前
qmhx发布了新的文献求助10
15秒前
15秒前
顾矜应助drew采纳,获得30
16秒前
汤姆完成签到 ,获得积分10
16秒前
16秒前
BBIBBI完成签到,获得积分10
17秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Photosynthesis III 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3071500
求助须知:如何正确求助?哪些是违规求助? 2725527
关于积分的说明 7489890
捐赠科研通 2372698
什么是DOI,文献DOI怎么找? 1258220
科研通“疑难数据库(出版商)”最低求助积分说明 610233
版权声明 596916